Artículos de revistas
Botulinum toxin for modulating the muscle strength of patients rehabilitated with zygomatic implants
Toxina botulínica para modulação da força muscular de pacientes reabilitados por implantes zigomáticos
Fecha
2019-01-01Registro en:
Brazilian Dental Science, v. 22, n. 2, p. 220-227, 2019.
2178-6011
10.14295/bds.2019.v22i2.1657
2-s2.0-85067277236
5130377144315365
0000-0002-1074-5319
Autor
Faculty of Dentistry of São Paulo Dental Surgeons Association (FAOA / APCD)
Universidade Estadual Paulista (Unesp)
Institución
Resumen
Objective: To measure the intensity of muscle strength and electrical activity of masseter and anterior temporal muscles based on BTX-A therapy in patients rehabilitated with total prostheses on zygomatic implants. Material and Methods: The object of the study was a sample of 20 individuals subjected to zygomatic implant surgery and rehabilitated with implant-supported prostheses, in order to obtain electromyographic data using an eight-channel module (EMG System do Brasil). The data were collected for three consecutive months: prior to the application (single dose) of BTX-A (30 U/ masseter muscle; 10 U/temporal muscle) and after 30 and 90 days of therapeutic treatment. Result: All muscle groups studied showed reduction of muscle electrical activity during voluntary contraction after 30 days of treatment (around 47%) (p < 0.001), which progressively reverted after 90 days of treatment. The anterior temporal muscles presented similar motor behavior, with activity reduction of 39% (p < 0.05). There was a reduction of 17.68% (p < 0.05) in mandibular force and an increase of 14.22% (p < 0.05) in mouth opening after 30 days of BTX-A administration. Conclusions: The results suggest that BTX-A significantly reduces muscle activity, in either the recruitment of motor units or muscle tone, in the first three months of therapeutic treatment. This therapy may also be useful as a preventive method for the failure of zygomatic implant-supported prostheses.